Simplify Logo

Full-Time

QA Document Control Lead

Confirmed live in the last 24 hours

Legend Biotech

Legend Biotech

1,001-5,000 employees

Develops and commercializes cell therapies

Biotechnology
Healthcare

Senior

Bridgewater Township, NJ, USA

Position requires onsite presence in Raritan, NJ.

Category
QA & Testing
Quality Assurance
Requirements
  • A minimum of 6 years relevant work experience is required. It is preferable that the candidate have experience working in an aseptic manufacturing facility, preferably in quality assurance, manufacturing compliance, clinical quality, or cell therapy.
  • A minimum of a Bachelor’s Degree in Science, Information Science or equivalent is required.
Responsibilities
  • Day to day management of resources, planning and assigning work to Document Control Specialists to meet goals and deadlines.
  • Serve as a Document Control reviewer for new and revised procedures and documents to ensure compliance with global and site procedures as needed.
  • Ability to manage multiple and complex projects, provide status reports, and coordinate with cross-functional departments.
  • Support Document Management system users with workflow handling and electronic system usage, as needed.
  • Manage the periodic review process for procedures, as needed.
  • Issue batch related documentation and labels in support of GMP manufacturing.
  • Reconcile GMP documentation following document lifecycle requirements.
  • Create and issue GMP logbooks.
  • Responsible for storage and archival of GMP documents and batch related records.
  • Perform tasks in a manner consistent with the safety policies, quality systems and cGMP requirements.
  • Drive continuous improvement.
  • Have advanced computer skills to increase department’s productivity, as well as broadening technical and scientific knowledge.

Legend Biotech develops and sells cell therapies aimed at treating serious diseases, particularly cancers like hematological malignancies and solid tumors. Their approach is technology agnostic, allowing them to explore various methods to find effective treatments. The company operates in the personalized medicine sector, focusing on discovering, developing, and bringing new therapies to market. They generate revenue through licensing and selling their therapies, including CAR-T therapies, which involve modifying a patient's own cells to combat cancer. Unlike many competitors, Legend Biotech emphasizes transparency with investors, regularly updating them on financial results and business developments. Their goal is to provide effective treatments for hard-to-treat diseases through innovative cell therapy solutions.

Company Stage

IPO

Total Funding

$750.5M

Headquarters

Franklin Township, New Jersey

Founded

2014

Growth & Insights
Headcount

6 month growth

20%

1 year growth

44%

2 year growth

101%
Simplify Jobs

Simplify's Take

What believers are saying

  • Legend Biotech's recent European Commission approval for CARVYKTI® positions it as a leader in the multiple myeloma treatment market.
  • Strategic partnerships, such as the one with MaxCyte, enhance Legend Biotech's capabilities in cell engineering and expand its technological reach.
  • The company's commitment to transparency and investor relations, demonstrated through regular financial updates, fosters investor confidence and long-term stability.

What critics are saying

  • The competitive landscape in cell therapy and personalized medicine is intense, requiring continuous innovation to maintain market position.
  • Regulatory hurdles and the need for extensive clinical trials can delay the commercialization of new therapies, impacting revenue streams.

What makes Legend Biotech unique

  • Legend Biotech's technology-agnostic approach allows it to explore multiple innovative therapies, unlike competitors who may focus on a single technology.
  • The company's comprehensive business model, from discovery to commercialization, ensures control over the entire treatment lifecycle, providing a competitive edge.
  • Legend Biotech's strong focus on CAR-T therapies, particularly for hematological malignancies and solid tumors, sets it apart in the personalized medicine sector.

Help us improve and share your feedback! Did you find this helpful?